BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37782106)

  • 21. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
    Chitrangi S; Vaity P; Jamdar A; Bhatt S
    BMC Cancer; 2023 Jul; 23(1):689. PubMed ID: 37479967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
    Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
    Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
    Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
    Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organoid Modeling of the Tumor Immune Microenvironment.
    Neal JT; Li X; Zhu J; Giangarra V; Grzeskowiak CL; Ju J; Liu IH; Chiou SH; Salahudeen AA; Smith AR; Deutsch BC; Liao L; Zemek AJ; Zhao F; Karlsson K; Schultz LM; Metzner TJ; Nadauld LD; Tseng YY; Alkhairy S; Oh C; Keskula P; Mendoza-Villanueva D; De La Vega FM; Kunz PL; Liao JC; Leppert JT; Sunwoo JB; Sabatti C; Boehm JS; Hahn WC; Zheng GXY; Davis MM; Kuo CJ
    Cell; 2018 Dec; 175(7):1972-1988.e16. PubMed ID: 30550791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2-013-derived organoid.
    Tanaka C; Furihata K; Naganuma S; Ogasawara M; Yoshioka R; Taniguchi H; Furihata M; Taniuchi K
    Hum Cell; 2022 Mar; 35(2):735-744. PubMed ID: 35150409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
    Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
    J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor organoid models in precision medicine and investigating cancer-stromal interactions.
    Xu R; Zhou X; Wang S; Trinkle C
    Pharmacol Ther; 2021 Feb; 218():107668. PubMed ID: 32853629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organoid of ovarian cancer: genomic analysis and drug screening.
    Liu HD; Xia BR; Jin MZ; Lou G
    Clin Transl Oncol; 2020 Aug; 22(8):1240-1251. PubMed ID: 31939100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
    BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays.
    van Biljon L; Fashemi B; Rodriguez J; Graham O; Compadre A; Fuh K; Khabele D; Mullen M
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36912550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.
    Girda E; Huang EC; Leiserowitz GS; Smith LH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1701-1707. PubMed ID: 28683005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
    Hu H; Sun C; Chen J; Li Z
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):146. PubMed ID: 38509422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
    Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
    Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
    Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
    Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
    Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
    Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organoid Models for Precision Cancer Immunotherapy.
    Sun CP; Lan HR; Fang XL; Yang XY; Jin KT
    Front Immunol; 2022; 13():770465. PubMed ID: 35450073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrogel-based colorectal cancer organoid co-culture models.
    Luo X; Fong ELS; Zhu C; Lin QXX; Xiong M; Li A; Li T; Benoukraf T; Yu H; Liu S
    Acta Biomater; 2021 Sep; 132():461-472. PubMed ID: 33388439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting.
    Aizawa Y; Takada K; Aoyama J; Sano D; Yamanaka S; Seki M; Kuze Y; Ramilowski JA; Okuda R; Ueno Y; Nojima Y; Inayama Y; Hatakeyama H; Hatano T; Takahashi H; Nishimura G; Fujii S; Suzuki Y; Taniguchi H; Oridate N
    Cell Oncol (Dordr); 2023 Apr; 46(2):409-421. PubMed ID: 36538240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
    Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
    Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.